X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs JUBILANT LIFE SCIENCES - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON JUBILANT LIFE SCIENCES BIOCON /
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 18.6 12.9 143.4% View Chart
P/BV x 2.9 1.8 160.2% View Chart
Dividend Yield % 0.4 0.6 61.8%  

Financials

 BIOCON    JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    BIOCON
Mar-18
JUBILANT LIFE SCIENCES
Mar-18
BIOCON /
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,1881,039 114.3%   
Low Rs305600 50.8%   
Sales per share (Unadj.) Rs68.7482.6 14.2%  
Earnings per share (Unadj.) Rs7.640.7 18.5%  
Cash flow per share (Unadj.) Rs14.067.4 20.7%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %0.10.4 36.6%  
Book value per share (Unadj.) Rs86.3262.3 32.9%  
Shares outstanding (eoy) m600.00155.79 385.1%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.91.7 639.6%   
Avg P/E ratio x98.920.1 491.2%  
P/CF ratio (eoy) x53.412.2 439.3%  
Price / Book Value ratio x8.63.1 276.7%  
Dividend payout %13.27.4 179.8%   
Avg Mkt Cap Rs m447,900127,670 350.8%   
No. of employees `0006.12.4 252.4%   
Total wages/salary Rs m9,31115,559 59.8%   
Avg. sales/employee Rs Th6,705.830,861.4 21.7%   
Avg. wages/employee Rs Th1,514.26,387.0 23.7%   
Avg. net profit/employee Rs Th736.92,604.4 28.3%   
INCOME DATA
Net Sales Rs m41,23475,178 54.8%  
Other income Rs m2,062400 515.1%   
Total revenues Rs m43,29675,579 57.3%   
Gross profit Rs m8,29115,184 54.6%  
Depreciation Rs m3,8514,151 92.8%   
Interest Rs m6152,843 21.6%   
Profit before tax Rs m5,8878,591 68.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,247 69.8%   
Profit after tax Rs m4,5316,344 71.4%  
Gross profit margin %20.120.2 99.6%  
Effective tax rate %26.726.2 101.9%   
Net profit margin %11.08.4 130.2%  
BALANCE SHEET DATA
Current assets Rs m41,48631,898 130.1%   
Current liabilities Rs m21,41320,047 106.8%   
Net working cap to sales %48.715.8 308.8%  
Current ratio x1.91.6 121.8%  
Inventory Days Days6468 94.7%  
Debtors Days Days9455 171.5%  
Net fixed assets Rs m50,66160,715 83.4%   
Share capital Rs m3,000156 1,925.5%   
"Free" reserves Rs m48,80840,710 119.9%   
Net worth Rs m51,80840,865 126.8%   
Long term debt Rs m17,89830,478 58.7%   
Total assets Rs m99,89796,176 103.9%  
Interest coverage x10.64.0 262.9%   
Debt to equity ratio x0.30.7 46.3%  
Sales to assets ratio x0.40.8 52.8%   
Return on assets %5.29.6 53.9%  
Return on equity %8.715.5 56.3%  
Return on capital %9.616.0 60.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05814,402 83.7%   
Fx outflow Rs m7,34812,044 61.0%   
Net fx Rs m4,7102,358 199.7%   
CASH FLOW
From Operations Rs m6,62113,032 50.8%  
From Investments Rs m-6,840-6,177 110.7%  
From Financial Activity Rs m-2,397-9,011 26.6%  
Net Cashflow Rs m-2,612-2,123 123.1%  

Share Holding

Indian Promoters % 40.4 45.6 88.6%  
Foreign collaborators % 20.6 3.5 588.6%  
Indian inst/Mut Fund % 8.4 8.7 96.6%  
FIIs % 10.7 21.2 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.1 94.3%  
Shareholders   109,995 23,815 461.9%  
Pledged promoter(s) holding % 0.0 15.9 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Capital Goods and Realty Stocks Lag(09:30 am)

Asian share markets are mixed today. The Shanghai Composite is lower by 0.3% while the Hang Seng is even. The Nikkei 225 is trading down by 0.7%.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 16, 2019 10:09 AM

TRACK BIOCON

BIOCON - VENUS REMEDIES COMPARISON

COMPARE BIOCON WITH

MARKET STATS